Research ArticleArticle

Is Screening for Hepatitis B and Hepatitis C Useful in Patients with Recent-Onset Polyarthritis? The ESPOIR Cohort Study

XAVIER GUENNOC, VALÉRIE NARBONNE, SANDRINE JOUSSE-JOULIN, VALERIE DEVAUCHELLE-PENSEC, MAXIME DOUGADOS, JEAN PIERRE DAURÈS and ALAIN SARAUX
The Journal of Rheumatology July 2009, 36 (7) 1407-1413; DOI: https://doi.org/10.3899/jrheum.081308

REFERENCES

  1. 1.↵
    1. Vassilopoulos D,
    2. Calabrese LH
    . Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther 2008;10:215.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Saraux A,
    2. Fautrel B,
    3. Maillefert JF,
    4. et al
    . Laboratory and imaging studies used by French rheumatologists to evaluate patients with early arthritis. J Rheumatol 2006;33:897–902.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Fautrel B,
    2. Saraux A,
    3. Maillefert JF,
    4. et al
    . Costs of workups for the diagnosis of early arthritis: results of a nationwide survey. Arthritis Rheum 2004;51:507–12.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Maillefert JF,
    2. Muller G,
    3. Falgarone G,
    4. et al
    . Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:635–7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Combe B,
    2. Benessiano J,
    3. Berenbaum F,
    4. et al
    . The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440–5.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Roudot-Thoraval F
    . Epidémiologie de l’hépatite C. Med Mal Infect 2000;30 suppl 1:27–33.
    OpenUrl
  7. 7.
    1. Roudot-Thoraval F,
    2. Bastie A,
    3. Pawlotsky JM,
    4. Dhumeaux D
    . Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485–90.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Dubois F,
    2. Desenclos JC,
    3. Mariotte N,
    4. Goudeau A
    . Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997;25:1490–6.
    OpenUrlCrossRefPubMed
  9. 9.
    1. Zarski JP
    . Epidemiology of chronic hepatitis B [French]. Presse Med 2006;35:304–7.
    OpenUrlCrossRefPubMed
  10. 10.
    1. CETAF, INVS, CPAM
    . Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs du virus de l’hépatite B chez les assurés sociaux du régime général de France métropolitaine, 2003–2004, 2005. [Internet; accessed April 19, 2009.] Available from: http://www.invs.sante.fr/publications/2005.
  11. 11.↵
    1. Cacoub P,
    2. Saadoun D,
    3. Bourliere M,
    4. et al
    . Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol 2005;43:764–70.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Zerrak A,
    2. Bour JB,
    3. Tavernier C,
    4. Dougados M,
    5. Maillefert JF
    . Usefulness of routine hepatitis C virus, hepatitis B virus, and parvovirus B19 serology in the diagnosis of recent-onset inflammatory arthritides. Arthritis Rheum 2005;53:477–8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Rivera J,
    2. Garcia-Monforte A,
    3. Pineda A,
    4. Millan Nunez-Cortes J
    . Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999;26:420–4.
    OpenUrlPubMed
  14. 14.↵
    1. Hsu FC,
    2. Starkebaum G,
    3. Boyko EJ,
    4. Dominitz JA
    . Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. J Rheumatol 2003;30:455–8.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Barbosa VS,
    2. Silva NA,
    3. Martins RM
    . Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. Braz J Med Biol Res 2005;38:801–5.
    OpenUrlPubMed
  16. 16.↵
    1. Vitali C,
    2. Sciuto M,
    3. Neri R,
    4. et al
    . Anti-hepatitis C virus antibodies in primary Sjogren’s syndrome: false positive results are related to hyper-gamma-globulinaemia. Clin Exp Rheumatol 1992;10:103–4.
    OpenUrlPubMed
  17. 17.↵
    1. Pavy S,
    2. Constantin A,
    3. Pham T,
    4. et al
    . Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388–95.
    OpenUrlCrossRefPubMed
  18. 18.
    1. Hagiyama H,
    2. Kubota T,
    3. Komano Y,
    4. Kurosaki M,
    5. Watanabe M,
    6. Miyasaka N
    . Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004;22:375–6.
    OpenUrlPubMed
  19. 19.
    1. Ostuni P,
    2. Botsios C,
    3. Punzi L,
    4. Sfriso P,
    5. Todesco S
    . Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686–7.
    OpenUrlFREE Full Text
  20. 20.
    1. Ito S,
    2. Nakazono K,
    3. Murasawa A,
    4. et al
    . Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001;44:339–42.
    OpenUrlCrossRefPubMed
  21. 21.
    1. Narvaez J,
    2. Rodriguez-Moreno J,
    3. Martinez-Aguila MD,
    4. Clavaguera MT
    . Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998;25:2037–8.
    OpenUrlPubMed
  22. 22.↵
    1. Flowers MA,
    2. Heathcote J,
    3. Wanless IR,
    4. et al
    . Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990;112:381–2.
    OpenUrlPubMed
  23. 23.↵
    1. Fautrel B,
    2. Constantin A,
    3. Morel J,
    4. et al
    . Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. Joint Bone Spine 2006;73:433–41.
    OpenUrlCrossRefPubMed
  24. 24.
    1. Pham T,
    2. Guillemin F,
    3. Claudepierre P,
    4. et al
    . TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 2006;73:547–53.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Oniankitan O,
    2. Duvoux C,
    3. Challine D,
    4. et al
    . Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107–9.
    OpenUrlAbstract/FREE Full Text
  26. 26.
    1. Tsutsumi Y,
    2. Kanamori H,
    3. Mori A,
    4. et al
    . Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599–608.
    OpenUrlCrossRefPubMed
  27. 27.
    1. Perceau G,
    2. Diris N,
    3. Estines O,
    4. Derancourt C,
    5. Levy S,
    6. Bernard P
    . Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053–6.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Aksoy S,
    2. Abali H,
    3. Kilickap S,
    4. Erman M,
    5. Kars A
    . Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin’s lymphoma patient. Clin Lab Haematol 2006;28:211–4.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section